Round Table on Malignant Hyperthermia in Physically Active Populations: Meeting Proceedings by Adams, William M. & NC DOCKS at The University of North Carolina at Greensboro
Round Table on Malignant Hyperthermia in Physically Active Populations: Meeting 
Proceedings 
 
By: Yuri Hosokawa, Douglas J. Casa, Henry Rosenberg, John F. Capacchione, Emmanuel 
Sagui, Sheila Riazi, Luke N. Belval, Patricia A. Deuster, John F. Jardine, Stavros A. 
Kavouras, Elaine C. Lee, Kevin C. Miller, Sheila M. Muldoon, Francis G. O'Connor, Scott R. 
Sailor, Nyamkhishig Sambuughin, Rebecca L. Stearns, William M. Adams, Robert A. Huggins, 
and Lesley W. Vandermark 
 
Hosokawa Y, Casa DJ, Rosenberg H, Cappacchione JF, Sagui E, Riazi S, Belval LN, Deuster 
PA, Jardine JF, Kavouras SA, Lee EC, Miller KC, Muldoon SM, O’Connor FG, Sailor SR, 
Sambuughin N, Stearns RL, Adams WM, Huggins RA, Vandermark LW. Round Table on 
Malignant Hyperthermia in Physically Active Populations: Meeting Proceedings. Journal of 
Athletic Training. 2017;52(4):377-383. 
 
Made available courtesy of the National Athletic Trainers’ Association: 
https://doi.org/10.4085/1062-6050-52.2.06 
 
***© National Athletic Trainers’ Association, Inc. Reprinted with permission. No further 
reproduction is authorized without written permission from the National Athletic Trainers’ 
Association. This version of the document is not the version of record. *** 
 
***Note: Tables may be found at the end of this document. 
 
Abstract: 
 
Context: Recent case reports on malignant hyperthermia (MH)-like syndrome in physically 
active populations indicate potential associations among MH, exertional heat stroke (EHS), and 
exertional rhabdomyolysis (ER). However, an expert consensus for clinicians working with these 
populations is lacking. Objective: To provide current expert consensus on the (1) definition of 
MH; (2) history, etiology, and pathophysiology of MH; (3) epidemiology of MH; (4) association 
of MH with EHS and ER; (5) identification of an MH-like syndrome; (6) recommendations for 
acute management of an MH-like syndrome; (7) special considerations for physically active 
populations; and (8) future directions for research. Setting: An interassociation task force was 
formed by experts in athletic training, exercise science, anesthesiology, and emergency 
medicine. The “Round Table on Malignant Hyperthermia in Physically Active Populations” was 
convened at the University of Connecticut, Storrs, September 17–18, 2015. Conclusions: 
Clinicians should consider an MH-like syndrome when a diagnosis of EHS or ER cannot be fully 
explained by clinical signs and symptoms presented by a patient or when recurrent episodes of 
EHS or ER (or both) are unexplained. Further research is required to elucidate the genetic and 
pathophysiological links among MH, EHS, and ER. 
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Article: 
 
Recent advances in the understanding of malignant hyperthermia (MH) warrant that sports 
medicine professionals recognize the associations among the ryanodine receptor 1 (RYR1), 
exertional heat stroke (EHS), and exertional rhabdomyolysis (ER).1−6 Although MH has been 
listed as one of the potential predisposing medical conditions for EHS in the National Athletic 
Trainers' Association (NATA) position statement on exertional heat illnesses,7 currently no 
consensus has been published on the implications of MH in physically active populations. 
 
OBJECTIVES 
 
The “Round Table on Malignant Hyperthermia in Physically Active Populations” was convened 
by the Korey Stringer Institute at the University of Connecticut, Storrs, on September 17–18, 
2015, to discuss MH and explore the potential associations among MH, EHS, and ER in 
physically active populations. Researchers, medical professionals, and members of the NATA 
were assembled at the meeting. The round-table agenda consisted of 4 major aims: (1) provide an 
overview of MH, (2) identify the epidemiology and diagnosis of MH, (3) discuss the 
management and potential outcomes of MH, and (4) evaluate the current evidence linking or 
distinguishing MH, EHS, and ER in physically active populations. 
 
Definition of Malignant Hyperthermia 
 
Malignant hyperthermia (MH) is an anesthetic-induced, autosomal-dominant, pharmacogenetic 
disorder of skeletal muscle, triggered by inhalation anesthetic agents or succinylcholine and 
resulting in hypermetabolism, skeletal muscle damage, hyperthermia, and if left untreated, death. 
 
The MH-like syndrome is a nonanesthetic-induced, often exertion-related episode, presenting 
with 2 or more of the following signs and symptoms: markedly elevated body temperature, 
muscle pain with muscle breakdown, and muscle rigidity. This syndrome is often identified in 
the absence of another readily identifiable diagnosis; these patients require further evaluation to 
assess the cause of their signs and symptoms. 
 
History, Cause, and Pathophysiology of MH 
 
Michael Denborough, MD, and his colleagues first described MH in the early 1960s.8 Later that 
decade, Beverly Britt, MD, conducted pioneering research on the occurrence and manifestations 
of MH.9 This seminal work demonstrated that MH was precipitated by exposure to potent 
inhalational anesthetics and the paralyzing agent succinylcholine but not to other anesthetics. 
The MH syndrome was determined to be inherited in an autosomal-dominant manner and was 
independent of ethnicity.10,11 
 
Skeletal muscle from MH-susceptible individuals displayed an accentuated muscle-contraction 
response when exposed to the anesthetic halothane and to calcium-releasing agents such as 
caffeine.12 It became clear that MH was a muscle disorder caused by uncontrolled calcium 
release from the sarcoplasmic reticulum. In the 1990s, MH susceptibility was genetically linked 
to the skeletal muscle-specific calcium channel RYR1. Mutations of RYR1 are found in 
approximately 70% of MH-susceptible patients.13 Hundreds of DNA variants exist for 
the RYR1 gene, but fewer than 40 have been definitively identified as causing 
MH.14 Additionally, although many proteins regulate calcium flux, another gene, calcium 
channel, voltage-dependent, L type, alpha 1S subunit (CACNA1S), has been associated with MH 
in fewer than 1% of cases.15 It should be noted that genetic changes in the RYR1 are also found in 
a variety of muscle disorders (eg, central core disease) that demonstrate abnormal histopathology 
and result in muscle weakness. The muscle weakness in these myopathies is caused by 
reductions in calcium release and muscle activation.16 
 
The pathophysiology of MH is linked to the impairment of myoplasmic calcium homeostasis, 
which leads to increased muscle tension and metabolism. Malignant hyperthermia manifests as 
increased production of carbon dioxide and heart rate and is often accompanied by accentuated 
muscle rigidity, hyperkalemia, increased acid content in the blood, release of myoglobin into the 
urine, and release of the muscle enzyme creatine kinase.1 Downstream metabolic effects include 
adenosine triphosphate breakdown and increased cell membrane leakage and acidosis. 
Hypermetabolism also results in hyperthermia that may reach fatal levels of greater than 40.5°C 
(105°F), which may lead to symptoms such as failure of the blood coagulation system.17 
 
Through the 1970s, MH mortality was close to 80%.9 When anesthesiologists were made aware 
of the signs of MH and the steps required to treat it, mortality rates declined.18 However, a 
specific antidote, dantrolene sodium, was not approved by the Federal Drug Administration until 
1979. The efficacy of dantrolene was demonstrated first in naturally occurring breeds of heavily 
muscled swine and then tested in humans.19 With the widespread use of dantrolene sodium, 
mortality rates decreased to 15% or lower. Most developed countries now require dantrolene to 
be available in all operating rooms, yet in many parts of the world, this is not standard practice, 
despite the very high likelihood that a patient who develops MH will die without the 
administration of dantrolene. 
 
Although early MH researchers discovered the syndrome in association with exposure to 
anesthetics, MH was also observed to develop in specific breeds of pigs exposed to 
nonpharmacologic stress, environmental heat stress, or exercise. Four decades ago, Wingard and 
Gatz20 hypothesized that EHS and MH could be 2 phenotypes of a latent skeletal muscle 
disorder. This hypothesis was substantiated by later case reports suggesting that human patients 
may also present with an MH-like syndrome on exposure to exertion and environmental heat 
stress in the absence of anesthesia. Not all cases of EHS are due to the calcium-dependent 
pathophysiology of MH, but the relationship between MH-like syndromes and MH is under 
intensive study.4 
 
Epidemiology of MH 
 
Current Knowledge. 
 
1. Episodes of MH occur predominantly in young, muscular males.21,22 All ethnicities are 
affected. The estimated incidence of MH is 1 in 250 000 surgeries involving all types of 
anesthesia and 1 in 62 000 uses of potent inhalational anesthetics or succinylcholine.23 In a 
study21 of New York hospitals, the prevalence rate of MH was 0.96 per 100 000 surgical 
discharges. 
 
2. Malignant hyperthermia has a variable presentation, ranging from a full metabolic crisis after 
induction of anesthesia to a slowly appearing reaction up to 1 hour after termination of 
anesthesia. The penetrance is also variable, meaning that MH-susceptible patients do not 
develop the syndrome with every exposure to triggering agents.1,22 
 
3. The condition is a genetically heterogeneous disorder, with variants in 
the RYR1 and CACNA1S genes responsible for 50% to 75% and 1% of MH cases, 
respectively.24 The prevalence of genetic variants associated with MH susceptibility was 
estimated at 1 in 3000.1,25 To date, 34 RYR1 variants and 2 CACNA1S variants have been 
confirmed as causing MH and recommended for diagnostic genetic testing by the European 
Malignant Hyperthermia Group.14 
 
4. Nonanesthesia-related MH-like syndromes may share a common pathogenic mechanism with 
MH. This possibility is based on similarities of the clinical signs (Table 1), the presence of 
an RYR1 variant in 30% of patients, and a positive in vitro contracture test or caffeine 
halothane contracture rest test (CHCT) in 45% of this population.2,4,26 
 
Gaps in Current Knowledge. 
 
1. The true incidence of MH episodes remains unknown due to the variable genetic penetrance 
and presentation and the fact that most MH-susceptible patients are asymptomatic before an 
MH event. The functional consequences of hundreds of reported RYR1 variants and the 
possible association with MH remain unknown. The risk of MH among EHS and ER patients 
and the risk of EHS and ER in MH-susceptible patients have not yet been ascertained. 
 
2. To date, it is unclear if MH-susceptible patients should avoid performing strenuous exercise 
in hot or humid environments or if anesthetic triggers should be avoided in patients with a 
history of EHS. Because the in vitro contracture test and CHCT are designed for diagnosis in 
patients with a personal or family history of MH, the appropriateness of applying MH-
diagnostic functional bioassays to all unexplained or recurrent cases of EHS and ER is 
debatable. 
 
3. A small number of studies suggest the use of B cell bioassay as a possible alternative to the 
CHCT.27 
 
4. The potential utility of dantrolene in the treatment of EHS and ER is controversial due to the 
lack of randomized controlled clinical studies in patients with these conditions.28 
 
Association of MH with EHS and ER 
 
Current Knowledge. 
 
1. Multiple MH-like syndrome case reports and case series suggest similarities and associations 
among MH-susceptible, EHS, and ER patients (Table 2).6,9–35 
 
2. Common signs and symptoms among the 3 conditions include hyperthermia, 
hypermetabolism, and muscle breakdown, resulting in death if untreated. 
 
3. The MH-like syndrome, EHS, and ER are mechanistically similar in that they share triggers 
such as exercise, hot or humid environmental conditions, and recent illness.31 
 
4. In unexplained or recurrent cases of EHS and ER, MH susceptibility has been reported, 
which suggests involvement of MH-related genetic mutations as some of the underlying risk 
factors for EHS and ER.30,31 
 
5. Assessing an MH-like syndrome includes neuromuscular evaluation and, in the absence of a 
clinical diagnosis, muscle biopsy and CHCT or genetic screening. Ongoing research will 
define the relationship among MH-like syndromes, EHS, and ER. 
 
Gaps in Current Knowledge. 
 
1. Genetic susceptibility may partially define low exercise or heat tolerance in patients with 
MH-like syndrome, but much remains unknown. 
 
2. Whether MH-susceptible individuals are at increased risk of developing EHS and ER is 
uncertain. Similarly, we do not know if patients with a history of EHS or ER are at increased 
risk of developing intraoperative MH. 
 
Identification of MH-Like Syndrome 
 
Current Knowledge. 
 
1. The MH-like syndrome is challenging to identify in physically active individuals because it 
lacks consistent diagnostic genotypes or phenotypes. Care providers should be on the alert 
when the nonanesthetized patient presents with MH-like syndrome signs and symptoms after 
other differential diagnoses have been exhausted. 
 
2. Diagnosis of an MH-like syndrome in the field without prior knowledge of an individual's 
susceptibility to the condition is not possible due to its nonspecific signs and symptoms. 
However, the condition should be considered in the differential diagnosis when other 
possibilities have been excluded (Table 1). Family members, if available, can provide useful 
information about a history of anesthesia intolerance, a personal or family history of MH, or 
concurrent medications or supplements that may be risk factors. If awake, the patient should 
be asked about any personal or familial history of adverse reactions to volatile anesthesia. 
 
3. The MH-like syndrome is usually diagnosed retrospectively after a patient undergoes 
advanced medical testing at an MH referral center or when an MH episode occurs under 
anesthesia. The MH-like syndrome has also been associated with myopathies (eg, central 
core disease) and recent viral illness.36 
 
4. Clinical signs at the time of presentation include an elevated end-tidal CO2 (indicating a 
hypermetabolic state), muscle rigidity (particularly masseter muscle spasms), rapid heart rate, 
and high body temperature; the end result is muscle breakdown, myoglobinuria, an elevated 
creatine kinase level (>10 000 U/L), or a slow or inadequate response to cooling strategies (or 
a combination of these). 
 
5. The most accurate way to diagnose MH susceptibility is by having a patient undergo an in 
vitro CHCT.1 However, this is a costly and invasive test, which requires a muscle biopsy. 
The sensitivity of the test is greater than 95%, but the specificity is about 80%.37 Patients 
with positive results to either caffeine or halothane or to both tests are classified as MH 
susceptible.1 
 
6. Although functionally tested MH-causative RYR1 and CACNA1S gene mutations have been 
identified, many novel variants of unknown significance have not been functionally 
characterized. Thus, the identification of novel variants of unknown significance cannot 
confirm the diagnosis of MH. Furthermore, the absence of RYR1 and CACNA1S mutations or 
variants cannot rule out MH, as genes that have not yet been identified may also confer MH 
susceptibility.1 
 
7. Determination of MH susceptibility requires expert advice concerning the choice of test and 
interpretation of the results. 
 
Recommendations for Acute Management of MH-Like Syndrome 
 
The Malignant Hyperthermia Association of the United States (MHAUS) is a valuable resource 
for information about MH and its treatment.38 The MHAUS provides a hotline with direct access 
to providers for real-time management of patients with MH and MH-like 
syndrome.1 Recommendations for acute care based on our knowledge to date using the Strength 
of Recommendation Taxonomy39 are as follows: 
 
1. Initial attention should focus on basic life support with rapid interventions for those who may 
require airway management or early chest compressions and defibrillation. Evidence 
Category: C 
 
2. Clinicians must obtain a rectal temperature to confirm initial body temperature and any 
changes. Any patient with a rectal temperature greater than 40.5°C (105°F) with coexisting 
signs or symptoms of central nervous system dysfunction should be aggressively cooled 
before being transported to a hospital. Whole-body immersion in cold water is recommended 
until rectal temperature is reduced to 38.3°C to 38.9°C (101°F−102°F).1,40,41 Other methods, 
such as wrapping in ice-chilled or filled towels or sheets or providing chilled intravenous 
fluids and ice packs are acceptable only during transport or when whole-body water 
immersion is not available.42,43 Evidence Category: C 
 
3. If an MH-like syndrome is suspected or known to be present, succinylcholine is 
contraindicated because it will exacerbate an MH crisis. Similarly, volatile anesthetics are 
contraindicated in anyone suspected of having experienced an MH-like crisis. Evidence 
Category: C 
 
4. If the clinician suspects an MH-like syndrome, the receiving hospital should be notified (ie, 
“code blue”) to have an anesthesiologist or another provider with experience in MH available 
to prepare dantrolene. Evidence Category: C 
 
5. When an MH-like syndrome is suspected, administration of intravenous dantrolene should be 
considered on the patient's arrival at the hospital.1 The initial dose of dantrolene is 2.5 mg/kg 
intravenously, repeated as needed every 10 to 15 minutes to control signs of the crisis. 
Dantrolene is a relatively benign medication in the normal population but may induce some 
muscle weakness. Aggressive cooling is also warranted if the patient is hyperthermic. After 
initial treatment, the patient should be admitted to the intensive care unit for 24 to 36 hours to 
be monitored for recurrence of an MH-like syndrome.36 Evidence Category: C 
 
Special Considerations for Physically Active Populations 
 
Given the potential associations among MH, EHS, and ER, clinicians who work with physically 
active populations may implement the following practices to prevent and mitigate the risk of 
potential MH events. 
 
1. Team physicians should add questions regarding MH to the athlete's preparticipation 
examination (Table 3). If the evaluation identifies a risk (yes to a previous history of MH, 
complications with anesthesia, or recurrent EHS or ER), referral to a neuromuscular 
specialist is encouraged for electromyography and muscle histology testing is encouraged to 
investigate a differential diagnosis of myopathy. Genetic testing and counseling may also be 
required. Currently, 5 CHCT testing sites are available in North America (Uniformed 
Services University of the Health Sciences, University of California-Davis, University of 
Minnesota, University of Toronto, and Wake Forest University). A complete genetic workup 
may cost $3000 to $5000, and RYR1 screening is approximately $1000. A commercial 
laboratory, PreventionGenetics (Marshfield, WI), offers genetic testing for MH and multiple 
other genetic disorders. The Robert Guthrie Biochemical & Molecular Genetics Laboratory 
at Buffalo General Hospital (Buffalo, NY) also offers genetic testing for MH and related 
disorders. Evidence Category: C 
 
2. Create an MH-like syndrome-specific emergency action plan for acute referral of a patient 
from the field to the hospital. If an MH-like syndrome is suspected, the first responder (eg, 
athletic trainer, team physician) should notify emergency medical services and the receiving 
hospital about any previous history of adverse reactions to anesthesia and instruct them to 
avoid the use of succinylcholine and volatile anesthetics. Additionally, the first responder 
should prompt the hospital to prepare dantrolene in case of fulminant MH. It should be noted 
that the lack of a previous history of complications from anesthesia does not eliminate the 
risk or concern for MH or MH-like episodes. Evidence Category: C 
 
3. Implement measures to address risk factors for EHS and ER. Probable risks for MH-like 
syndromes can be mitigated by optimizing hydration throughout exercise, providing athletes 
with heat-acclimatization periods before exercising in the heat for the first time, selecting 
exercise intensities that are appropriate for each individual, and avoiding physical activities 
when ill.40 Evidence Category: C 
 
4. Return-to-play considerations after an MH-like syndrome. Currently, no evidence-based 
guidelines exist to direct return-to-play after an MH-like event. The athlete's condition should 
be discussed with an appropriate consultant to guide a prudent reintroduction to activity, with 
careful attention to both exercise and environmental acclimatization. The athlete should 
obtain a medical alert bracelet, and the athletic training staff should be well prepared to 
implement the emergency action plan. Evidence Category: C 
 
5. Be aware of the potential risk during elective surgeries for injuries. If the family history 
suggests a risk of MH susceptibility, physicians should be notified to avoid the use of 
succinylcholine and volatile anesthetics. Severe cases of MH-like syndrome do not always 
occur at the patient's first exposure to these anesthetic triggers. A genetically susceptible 
patient may manifest clinical signs at any point in his or her life.29 Evidence Category: C 
 
6. Education for staff and athletes. If an athlete with known MH susceptibility is participating, 
the clinicians should develop an MH-specific emergency action plan and prepare an on-site 
cooling plan. Athletes with MH susceptibility should not exercise alone and should notify 
their medical providers (eg, athletic trainer, team physician) about the condition. 
Furthermore, clinicians should call the MHAUS 24-hour hotline at 800-644-9737 if they 
suspect a fulminant MH or MH-like syndrome. Evidence Category: C 
 
Future Directions for Research 
 
The clinical implications of MH in physically active populations constitute a critical gap in 
knowledge for researchers and medical professionals. We identify 3 main future areas of 
research to fill this gap: (1) evaluation of MH susceptibility in individuals with recurrent EHS or 
ER episodes of unknown cause, (2) tests to identify individuals with an MH-like syndrome, and 
(3) standard treatments of MH-like syndromes induced in an exercise-related setting. 
 
SUMMARY 
 
1. Researchers and clinicians should collaborate to expand databases on MH-susceptible 
patients to better identify links among MH, MH susceptibility, EHS, and ER. 
 
2. A definitive diagnosis of MH or an MH-like syndrome is currently limited to a positive result 
on CHCT testing. Genetic testing for RYR1 appears promising as a second diagnostic 
criterion. However, because not all genetic loci that are causal for MH have been identified, 
further refinement is necessary before large-scale testing is implemented. 
 
3. The field requires additional research to identify best practices for likely cases of an MH-like 
syndrome, in addition to cooling and other basic life-support actions. 
 
4. Research into the use of dantrolene for MH-like syndrome, EHS, and ER will determine its 
effectiveness in improving patient outcomes. 
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Table 1. Suggested Similarities Between Malignant Hyperthermia-Like Syndrome and Other Medical Diagnoses Based on Current Supporting Evidence 
 Predisposing Conditions Signs and Symptoms Treatment 
Medical Condition 
Genetic 
Mutation 
or Variant 
Positive 
Caffeine 
Halothane 
Contracture 
Test 
Family 
History of 
Adverse 
Reaction to 
Volatile 
Anesthetics 
Exposure 
to 
Anesthetic 
Agent 
Recent 
Illness 
Hot or 
Humid 
Environment 
Strenuous 
Exercise 
Low 
Exercise 
or Heat 
Tolerance 
Hyperthermia 
> 40°C Hypermetabolism 
Central 
Nervous 
System 
Dysfunction 
Increased 
Heart Rate 
Muscle 
Rigidity 
Flaccid 
Muscles Dantrolene 
Aggressive 
Cooling 
Malignant hyperthermia-like syndrome a a b NA a a c a b b a b b NA b b 
Malignant hyperthermia b b b b NA NA NA NA b b * b b NA b b 
Exertional heat stroke a NA NA NA b b b b b b b b NA b a b 
Exertional rhabdomyolysis a NA NA NA NA NA b a NA NA NA b NA NA a a 
Abbreviation: NA, not applicable according to the definition of the condition.  
a Inconclusive evidence to suggest association or effectiveness and requires further research.  
b Sufficient evidence to suggest a strong association or effectiveness.  
c Sufficient evidence to suggest the criterion is not a required characteristic. 
 
Table 2. Summary of Case Reports 
Characteristics Capacchione et al33 (2010) Lavezzi et al35 (2013) Potts et al6 (2014) 
Patient information African American male; 30 y old, 93 kg  
Physically fit  
Denied personal and family history of MH  
Denied heat intolerance 
White male; 6 y old, 20 kg  
Personal and family history of lordosis  
Denied family history of MH or heat or exercise 
intolerance  
No recent illness 
 Previous history of feeling overheated and 
stomach cramping while playing in the heat 
African American male; 30 y old  
Identical twin  
History of recurrent rhabdomyolysis with and 
without exercise  
Underwent 2 uncomplicated surgical procedures 
with general anesthesia as a child  
Denied personal or family history of MH 
African American male; 30 y old  
Identical twin; tested positive for MH 
susceptibility before elective surgery after twin 
brother tested positive on CHCT  
Oral dantrolene (100 mg tid) to treat muscle 
cramping and fatigue  
History of unexplained rhabdomyolysis  
History of cardiac arrest while under anesthesia 
Clinical presentations and 
diagnoses 
Initial: bilateral leg pain  
Secondary: rhabdomyolysis, bilateral compartment 
syndrome  
Tertiary: MH-like syndrome 
Initial: generalized seizure  
Secondary: MH-like syndrome  
Tertiary: death due to cardiac arrest 
Initial: chest pain  
Secondary: rhabdomyolysis  
Tertiary: exercise intolerance 
Initial: muscle cramping and fatigue  
Second: recurrent rhabdomyolysis 
Case description Bilateral calf pain after 2.5-mi walk, advised to 
rest, and discharged with diazepam and 
oxycodone/acetaminophen; increased leg pain in 
ensuing wk and diagnosed with exertional 
rhabdomyolysis and bilateral compartment 
syndrome; bilateral fasciotomies conducted 
without adverse reaction to inhalational 
anesthetics  
Next visit: irrigation and debridement of 
fasciotomy wound under general anesthesia led 
to total body rigidity (maximum nasal 
Lower extremity rigidity, trismus, and 
hyperthermia (40°C) after playing in splash pool 
for <10 min; unable to open mouth or speak 
clearly; generalized seizure with profuse 
sweating (rectal temperature = 42.7°C; heart rate 
= 190 bpm; cooling [IV, ice packs] ineffective); 
endotracheal tube placed using succinylcholine, 
but jaw did not relax, and cardiac arrest occurred 
Chest pain after working outside on hot summer 
day  
Visited emergency room; diagnosed with 
rhabdomyolysis; discharged after IV hydration  
Persistent exercise intolerance, severe muscle 
cramps with only moderate exertion, jaw and 
face cramps at rest, and developed complete 
inability to exercise 
Developed recurrent rhabdomyolysis with routine 
physical activity after discontinuing oral 
dantrolene  
Visited emergency room due to spontaneous 
muscle pain without exercise; discharged after 
IV hydration  
Revisited emergency room next day and referred 
to another hospital; stayed for 5 days and 
received IV hydration and opioid for pain 
control; no dantrolene administered and patient 
discharged home while still in pain  
Characteristics Capacchione et al33 (2010) Lavezzi et al35 (2013) Potts et al6 (2014) 
temperature = 38.5°C, end-tidal CO2 = 70 mm 
Hg, HR = 128 bpm)  
Hyperthermia (oral = temperature 39.4°C) with 
tachycardia (HR = 110 bpm) observed 
postoperation; dantrolene (240 mg) administered 
but rectal temperature rose to 39.7°C; additional 
dantrolene (1 mg/kg) administered 
Revisited emergency room 2 weeks later because 
muscle pain never resolved; dantrolene 
administered and patient discharged home with 
decreased pain and residual muscle weakness 
Diagnostic testing CHCT: positive for halothane, negative for 
caffeine  
Muscle histology: mild denervation atrophy  
Exercise-intolerance mutation panel test: negative 
Autopsy: negative for gross pathologic findings 
and infection 
CHCT: positive  
Muscle histology: normal 
Not applicable 
Genetic screening RYR1 variant Ser1342Gly in exon 28  
CACNA1S variant in Leu1800Ser in exon 44  
CASQ1 variant His66Arg in exon 1 
RYR1 Gly4820Arg in exon 100 RYR1 Arg2454Cys mutation RYR1 Arg2454Cys mutation 
Prognosis and additional 
testing 
No additional testing conducted RYR1 Gly4820Arg in exon 100 also found in 
decedent’s father and 2 siblings, all with lordosis  
Father positive on CHCT and muscle histology 
revealed central core disease 
Oral dantrolene (100 mg tid) to treat muscle 
cramping and fatigue  
Could not tolerate moderate exercise 
Could not tolerate moderate exercise 
Abbreviations: bpm, beats per minute; CHCT, caffeine halothane contracture test; HR, heart rate; IV, intravenous; MH, malignant hyperthermia; tid, 3 times per day 
 
Table 3. Preparticipation Examination Questions Regarding Malignant Hyperthermia 
1. Have you or has a family member been diagnosed with malignant hyperthermia? Have you ever been tested for malignant hyperthermia?  
2. Have you had 1 or more surgeries under anesthesia?  
a. Did you have any adverse reactions to anesthesia (eg, succinylcholine) during the surgery?  
b. Has a family member experienced any adverse reactions to anesthesia during surgery?  
3. Have you ever been diagnosed with exertional heat stroke?  
4. Have you ever been diagnosed with exertional rhabdomyolysis? 
 
 
 
